SCHEMBL23216831

SCHEMBL23216831

CN1CCC(C(NC(=O)C(F)(F)F)c2cc(Cl)c(Cl)cc2O)CC1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.39
ALOX12 P18054 2/20 0.39
RAB9A P51151 2/20 0.39
SSTR4 P31391 5/20 0.36
NCOA1 Q15788 1/20 0.36
NCOA3 Q9Y6Q9 1/20 0.36
HSP90AB1 P08238 2/20 0.35
GHSR Q92847 1/20 0.34
CCR8 P51685 4/20 0.33
HRH4 Q9H3N8 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
HSP90AA1 P07900 1/20 0.33
SSTR1 P30872 1/20 0.32
SLC6A2 P23975 1/20 0.32
SLC6A4 P31645 1/20 0.32
SLC6A3 Q01959 1/20 0.32
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29745153 1.00 NPC1 (0.39) NPC1ALOX12RAB9ASSTR4NCOA1
SCHEMBL23214819 0.85 HTR4 (0.39) NPC1ALOX12RAB9ASSTR4SSTR1
SCHEMBL29745505 0.85 HTR4 (0.39) NPC1ALOX12RAB9ASSTR4SSTR1
SCHEMBL23215391 0.84 AKT1 (0.39) NPC1ALOX12RAB9ANCOA1NCOA3
SCHEMBL29745487 0.84 AKT1 (0.39) NPC1ALOX12RAB9ANCOA1NCOA3
SCHEMBL23216063 0.78 FKBP1A (0.32) NPC1ALOX12RAB9A
SCHEMBL23216064 0.78 FKBP1A (0.32) NPC1ALOX12RAB9A
SCHEMBL6438142 0.76 F10 (0.50) SSTR4CCR8HRH4HRH3
SCHEMBL23215857 0.74 HRH4 (0.48) HRH4HRH3HSP90AA1SLC6A3
SCHEMBL23215944 0.74 HRH4 (0.48) HRH4HRH3HSP90AA1SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230023559-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC (US) 2023-01-26 US disclosed
US-20230023559-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC (US) 2023-01-26 US disclosed
WO-2021071806-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC (US) 2021-04-15 WO disclosed
WO-2021071806-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230023559-A1 ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS KCNJ2, KCNA3, KCNH3 NPC1 1807/4885ALOX12 4449/4885RAB9A 2049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.